The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the treatment's place in the nation's health plan formularies? [MEDPAGE Today]

"[Lenacapavir] is a highly effective and safe PrEP option administered every 6 months, which provides the potential to improve PrEP adherence and thus enhance HIV prevention in the United States," the CDC's PrEP Guidelines Work Group stated in its clinical recommendation, published last week in the Morbidity and Mortality Weekly Report.

More>

###